Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry of their products. Yoshii also provides his assessment of how low drug pricing is indirectly affecting the decisions of Mitsubishi Tanabe Pharma to base clinical trials in Korea.
I do not agree that we must wait for approvals from large markets if we can receive approvals at a faster pace from smaller markets like Korea and Taiwan, and thus allow patients to have access to medication
